BACKGROUND: Application of novel machine learning approaches to electronic health record (EHR) data could provide valuable insights into disease processes. We utilized this approach to build predictive models for progression to prediabetes and type 2 diabetes (T2D). METHODS: Using a novel analytical platform (Reverse Engineering and Forward Simulation [REFS]), we built prediction model ensembles for progression to prediabetes or T2D from an aggregated EHR data sample. REFS relies on a Bayesian scoring algorithm to explore a wide model space, and outputs a distribution of risk estimates from an ensemble of prediction models. We retrospectively followed 24 331 adults for transitions to prediabetes or T2D, 2007-2012. Accuracy of prediction models was assessed using an area under the curve (AUC) statistic, and validated in an independent data set. RESULTS: Our primary ensemble of models accurately predicted progression to T2D (AUC = 0.76), and was validated out of sample (AUC = 0.78). Models of progression to T2D consisted primarily of established risk factors (blood glucose, blood pressure, triglycerides, hypertension, lipid disorders, socioeconomic factors), whereas models of progression to prediabetes included novel factors (high-density lipoprotein, alanine aminotransferase, C-reactive protein, body temperature; AUC = 0.70). CONCLUSIONS: We constructed accurate prediction models from EHR data using a hypothesis-free machine learning approach. Identification of established risk factors for T2D serves as proof of concept for this analytical approach, while novel factors selected by REFS represent emerging areas of T2D research. This methodology has potentially valuable downstream applications to personalized medicine and clinical research.
BACKGROUND: Application of novel machine learning approaches to electronic health record (EHR) data could provide valuable insights into disease processes. We utilized this approach to build predictive models for progression to prediabetes and type 2 diabetes (T2D). METHODS: Using a novel analytical platform (Reverse Engineering and Forward Simulation [REFS]), we built prediction model ensembles for progression to prediabetes or T2D from an aggregated EHR data sample. REFS relies on a Bayesian scoring algorithm to explore a wide model space, and outputs a distribution of risk estimates from an ensemble of prediction models. We retrospectively followed 24 331 adults for transitions to prediabetes or T2D, 2007-2012. Accuracy of prediction models was assessed using an area under the curve (AUC) statistic, and validated in an independent data set. RESULTS: Our primary ensemble of models accurately predicted progression to T2D (AUC = 0.76), and was validated out of sample (AUC = 0.78). Models of progression to T2D consisted primarily of established risk factors (blood glucose, blood pressure, triglycerides, hypertension, lipid disorders, socioeconomic factors), whereas models of progression to prediabetes included novel factors (high-density lipoprotein, alanine aminotransferase, C-reactive protein, body temperature; AUC = 0.70). CONCLUSIONS: We constructed accurate prediction models from EHR data using a hypothesis-free machine learning approach. Identification of established risk factors for T2D serves as proof of concept for this analytical approach, while novel factors selected by REFS represent emerging areas of T2D research. This methodology has potentially valuable downstream applications to personalized medicine and clinical research.
Authors: Brian G Drew; Kerry-Anne Rye; Stephen J Duffy; Philip Barter; Bronwyn A Kingwell Journal: Nat Rev Endocrinol Date: 2012-01-24 Impact factor: 43.330
Authors: G Marchesini; M Brizi; G Bianchi; S Tomassetti; E Bugianesi; M Lenzi; A J McCullough; S Natale; G Forlani; N Melchionda Journal: Diabetes Date: 2001-08 Impact factor: 9.461
Authors: Barbora Vozarova; Norbert Stefan; Robert S Lindsay; Aramesh Saremi; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni Journal: Diabetes Date: 2002-06 Impact factor: 9.461
Authors: Philip J Barter; Kerry-Anne Rye; Jean-Claude Tardif; David D Waters; S Matthijs Boekholdt; Andrei Breazna; John J P Kastelein Journal: Circulation Date: 2011-07-18 Impact factor: 29.690
Authors: Abbas Dehghan; Mandy van Hoek; Eric J G Sijbrands; Theo Stijnen; Albert Hofman; Jacqueline C M Witteman Journal: Diabetes Care Date: 2007-07-10 Impact factor: 19.112
Authors: Heming Xing; Paul D McDonagh; Jadwiga Bienkowska; Tanya Cashorali; Karl Runge; Robert E Miller; Dave Decaprio; Bruce Church; Ronenn Roubenoff; Iya G Khalil; John Carulli Journal: PLoS Comput Biol Date: 2011-03-10 Impact factor: 4.475
Authors: Laura López-Ríos; Francisco J Nóvoa; Ricardo Chirino; Francisco Varillas; Mauro Boronat-Cortés; Ana M Wägner Journal: PLoS One Date: 2011-11-03 Impact factor: 3.240
Authors: Manuel Sanchez-Alavez; Iustin V Tabarean; Olivia Osborn; Kayo Mitsukawa; Jean Schaefer; Jeffrey Dubins; Kristina H Holmberg; Izabella Klein; Joe Klaus; Luis F Gomez; Hartmuth Kolb; James Secrest; Jeanine Jochems; Kevin Myashiro; Peter Buckley; John R Hadcock; James Eberwine; Bruno Conti; Tamas Bartfai Journal: Diabetes Date: 2009-10-21 Impact factor: 9.461
Authors: Michael J McGeachie; George L Clemmer; Boris Hayete; Heming Xing; Karl Runge; Ann Chen Wu; Xiaofeng Jiang; Quan Lu; Bruce Church; Iya Khalil; Kelan Tantisira; Scott Weiss Journal: J Allergy Clin Immunol Date: 2018-03-02 Impact factor: 10.793
Authors: Jeanne C Latourelle; Michael T Beste; Tiffany C Hadzi; Robert E Miller; Jacob N Oppenheim; Matthew P Valko; Diane M Wuest; Bruce W Church; Iya G Khalil; Boris Hayete; Charles S Venuto Journal: Lancet Neurol Date: 2017-09-25 Impact factor: 44.182
Authors: Martina Vettoretti; Enrico Longato; Alessandro Zandonà; Yan Li; José Antonio Pagán; David Siscovick; Mercedes R Carnethon; Alain G Bertoni; Andrea Facchinetti; Barbara Di Camillo Journal: BMJ Open Diabetes Res Care Date: 2020-07